Epcoritamab (CD3E; MS4A1/CD20) - Research Grid Biosimilar
Gecertificeerd

Epcoritamab (CD3E; MS4A1/CD20) - Research Grid Biosimilar

Catalog #: 10-978
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology.It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies.Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies.

Immunogen

Homo sapiens, Chimeric / CD3E; MS4A1/CD20 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG4-kappa-lambda

NCBI Organism

Homo sapiens

Other Product Names

GEN3013

Beschrijving

Epcoritamab (CD3E; MS4A1/CD20) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamEpcoritamab (CD3E; MS4A1/CD20) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-978